Pharmaceutical patents and public health: challenges for the Brazilian antiretroviral treatment policy

Meiners, C.M.M.d.A.

Cadernos de Saude Publica 24(7): 1467-1478

2008


ISSN/ISBN: 0102-311X
PMID: 18670671
DOI: 10.1590/s0102-311x2008000700002
Document Number: 206690
The high prices of patented drugs have fueled the debate regarding the impact of the intellectual property system on access to treatment, with a special focus on HIV/AIDS. The Brazilian policy for antiretroviral treatment, part of a comprehensive program that includes both disease prevention and health promotion activities, has allowed the country to meet goals for coverage and quality and has been considered a model for other countries. However, as the Brazilian STD/AIDS Program reaches maturity, the increasing incorporation of patented drugs into the AIDS treatment regimen imposes an increasing burden on the country's health budget. This article discusses the public health challenges raised by pharmaceutical patents and discusses possible ways to sustain the national policy for free, universal access to HIV/AIDS treatment.

Document emailed within 0-6 h
Secure & encrypted payments